Baron Funds, an investment management company, released its “Baron Health Care Fund” second-quarter 2025 investor letter. A copy of the letter can be downloaded here. The fund declined 5.06% ...

Mounjaro – which competes in the market with Novo Nordisk's GLP-1 agonist Ozempic (semaglutide) – was 8% better than ...

In May, the Danish pharma said CEO Lars Fruergaard Jørgensen would step down, following a turn in the obesity market. While Novo was the star of the emerging weight loss and diabetes market through ...

A variety of GLP-1 drugs that were developed to treat Type 2 diabetes, including Novo Nordisk’s Ozempic, have secured label ...

Indian pharma is hoping to cash in. Generic firms, such as Biocon, are already offering weight-loss drugs, such as cheaper ...

Eli Lilly said on Thursday that its newer diabetes drug Mounjaro outperformed Trulicity, its previously top-selling ...

Aggressive social media marketing by influencers has fuelled a surge in over-the-counter use of the diabetes and obesity ...

The Fed kept rates steady, as most economists had expected, but struck a more hawkish tone, causing a mid-afternoon stock sell-off.

FDA Commissioner Marty Makary spoke with Yahoo Finance about solving the food crisis, obesity crisis, and restoring trust in ...

Wall Street is reacting with downgrades to Novo's earnings, but with shares trading at their lowest valuation in years, ...

Law Offices of Howard G. Smith continues its investigation on behalf of Novo Nordisk A/S ("Novo Nordisk" or the "Company") (NYSE: NVO) investors concerning the Company's possible violations of federal ...

Compounding pharmacies are crimping sales of Novo Nordisk's obesity drug Wegovy by making what are essentially copies of the ...